SG
CLCD

Societe Generale’s CoLucid Pharmaceuticals, Inc. CLCD Stock Holding History

Societe Generale’s Portfolio CLCD Stock Details CLCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		$464K Buy
+56,769
New +$381K ﹤0.01% 1737

Other funds holding CLCD

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
EAM
EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $123B AUM 34.51% 1-Year Est. Return

Societe Generale's CLCD Position: Q2 2016 in Review

Societe Generale opened a new position in CoLucid Pharmaceuticals, Inc. (CLCD) in Q2 2016: 56,769 shares worth $464K. The stake represents ﹤0.01% of the portfolio and ranks #1737 among its holdings.

20 funds tracked by Wall St. Rank hold CLCD as of Q2 2016.

  • Societe Generale held 56,769 shares of CoLucid Pharmaceuticals, Inc. worth $464K as of Q2 2016.
  • CoLucid Pharmaceuticals, Inc. was a new Societe Generale position in Q2 2016.
  • CoLucid Pharmaceuticals, Inc. made up ﹤0.01% of Societe Generale's portfolio in Q2 2016, its #1737 holding.
  • 20 funds tracked by Wall St. Rank held CoLucid Pharmaceuticals, Inc. as of Q2 2016.

Based on Societe Generale's 13F filing for Q2 2016, filed 2 Aug 2016.